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FOCUS: Medication and Pregnancy
Medication Use During Pregnancy – What’s The Problem?
• A growing number of pregnant women are facing chronic health issues such as
diabetes, hypertension and depression.  
• Approximately 2/3 of women who give birth in the U.S. each year are prescribed
at least one medication other than a vitamin or mineral supplement during
pregnancy.
• There is a severe lack of clinical research on the effects of medications on pregnant
women and their fetuses.  Only a dozen medications are approved by the FDA for use
during pregnancy; all are for gestation or birth related issues such as anesthesia or
nausea.
• Healthcare providers are not always aware of which medications or dosages are
safe to prescribe during pregnancy.
• Consumers often have misperceptions about the safety of vitamins,
supplements or herbal remedies during pregnancy.   In addition, many
consumers do not report such use to their healthcare providers.
• Including pregnant women in clinical trials and research can bring a host of ethical
issues and decisions about fetal protection, maternal risk, and even paternal consent.

_________________________________________
Source: American Journal of Public Health

IPN’s Response
IPN is committed to providing timely, accurate information to health care professionals and
consumers about best practices during pregnancy.  
Among these efforts, Indiana Perinatal Network…
• Utilizes monthly e-bulletins and alerts to provide up-to-date communication on new
advances in research
• Convenes a Perinatal Mood Disorders Task Force to serve as a resource on medications that
can safely be used to treat depression during pregnancy
• Supports the State Breastfeeding Coordinator to stay current on medications that are safe
for women to take while breastfeeding
• Educates providers about screening and treatment of substance use during pregnancy;
in addition to alcohol and tobacco use, pregnant women are increasingly abusing prescription
medications
• Advocates for all healthcare providers to adopt a Learner’s Stance when interacting with
patients. The goal is to help providers learn to communicate more clearly with patients
about their pregnancies and to approach different cultural practices and health behaviors in a
respectful, nonjudgmental way.

Clinical Update: Medication Use in Pregnant Women with Chronic Medical Conditions
Deborah Zeitlin, Pharm.D. - Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences; Clinical
Pharmacist, Indiana Clinic Family Medicine Center, Clarian Health

A recent preliminary report from the National Center for
Health Statistics shows that the number of live births in the
United States decreased in 2008 1-- however, the rate of live
births per 1000 women has increased in women 40 to 49
years.  Older women potentially have already been diagnosed
and are actively being treated for chronic medical conditions
that include hypertension, asthma, diabetes and depression.  
Reports have shown 5% of pregnant women have hypertension
and the risk increases with age.2    Asthma incidence ranges
from 4% to 9% in pregnant women.3    Pre-existing diabetes
is prevalent in 12% of pregnant women in the United States.4
Finally, depression is very common in women between the ages
of 15 to 44 years.5
Chronic hypertension is more prevalent in women who are
obese, African-American and older than 35 years.   Untreated
hypertension may cause cardiovascular or cerebrovascular
events in the mother, but the fetus is at risk for premature birth,
perinatal mortality, interuterine growth restrictions, cesarean
delivery, and superimposed preeclampsia.6 Medications are
usually required in the third trimester or when the blood
pressure is greater than 160/105mmHg.   Avoidance of ACE
inhibitors and angiotensin-receptor blockers is necessary
to prevent renal agenesis and malformed cardiovascular
and central nervous systems.7    Helpful non-pharmacologic
recommendations include sodium restriction, appropriate
vitamin supplementation, exercise, and avoidance of alcohol
and tobacco.8
Untreated asthma may increase the need for hospitalization
or emergency room visits, oral corticosteroids, and cesarean
4

Vol. 14 • Issue 3 • 2010

delivery as well as the risk for preeclampsia, premature birth,
and low birth weight.6,9 Continuing current asthma medications
is safer than stopping therapy, and budesonide is the preferred
inhaled corticosteroid.10    Reinforcement of proper inhaler
technique, medication adherence, control of environmental
triggers and allergens, and smoking cessation is also beneficial
for pregnant women.11
Uncontrolled or poorly treated diabetes may cause spontaneous
abortions, increased birth weight, still births, interuterine
growth restrictions, and fetal abnormalities.12 The preferred
anti-diabetic agent is insulin, since it does not cross the
placenta.   When used appropriately it maintains glycemic
control and prevents hypoglycemia. NPH is the preferred
longer acting insulin.   All short acting insulins, regular,
lispro and aspart, are considered pregnancy category B by
the Food and Drug Administration (FDA).   Two oral agents
that may be used especially if they were successful prior to
pregnancy are metformin and glyburide.13 During pregnancy
it is still important to maintain good blood glucose levels with
appropriate monitoring, take a prenatal vitamin with sufficient
amount of folic acid, eat foods that are consistent with a diabetic
diet, and exercise regularly.14
Depressed mothers may want to stop medications when they
find out they are pregnant, but uncontrolled depression may
be more detrimental to the fetus than medications’ side effects.  
Risks to the mother include poor self-care and medication
adherence, suicidal ideation, illicit drug and alcohol usage, low
weight gain, postpartum depression and self-injury behavior.  
Ramifications to the fetus are premature birth, low birth weight,
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and admission to the neonatal intensive care unit upon delivery.
Ultimately the child may have delayed cognitive and emotional
development.6   When choosing an antidepressant always assess
the risks and benefits of a medication prior to use since there are
no efficacy trials.  Caution is warranted with paroxetine, since
the FDA classifies it as a pregnancy class D.  If an agent needs
to be started during pregnancy, ideally wait until after the first
trimester to minimize miscarriage and teratogenesis risks.15, 16
When treating pregnant women with chronic medical
conditions, always treat them to the appropriate goals of their
condition with recommended medications.  If possible, ensure
counseling prior to conception so the patient knows what
changes should be made for the safety of the fetus as well as
the mother.  With medication therapy weigh the risks of the
medications’ side effects from that of the condition.  Treatment
should also include non-pharmacologic therapy as well as
regular patient monitoring to ensure a safe pregnancy.
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